Fundraising Fox

Capsida

Founded 2019 · 36 employees on LinkedIn · 2 known investors

Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids. The company targets both central nervous system and ophthalmology conditions across all ages.

BiotechDeep TechDigital HealthMedical Devices

Founders & leadership

Capsida was founded in 2019 by Viviana Gradinaru, Nick Goeden, Ph.D., and Nicholas Flytzanis.

VG
Viviana Gradinaru
NG
Nick Goeden, Ph.D.Co-founder
NFNicholas Flytzanis
Nicholas FlytzanisCo-founder

Investors · 2

Westlake Village BioPartners✓ verifiedLos Angeles · $100K – $5M
Versant Ventures✓ verifiedSan Francisco · $250K – $5M

Competitors · 1

by search overlap
Bioworld33 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Capsida for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Press Releases - Capsida Biotherapeuticscapsida.com · Jun 2023Capsida Has a New Facility To Manufacture Treatments for ALS and Friedreich’s Ataxiadot.la · Jul 2021Capsida Biotherapeutics Raises $140M in Series A Funding - FinSMEsfinsmes.com · May 2021Capsida Debuts with $140 Million to Advance Next Generation Gene Therapies - Global Genesglobalgenes.org · Apr 2021Capsida raises $140 million for targeted AAV gene therapiescen.acs.org · Apr 2021

Frequently asked questions

What does Capsida do?
Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids. The company targets both central nervous system and ophthalmology conditions across all ages.
Who founded Capsida?
Capsida was founded by Viviana Gradinaru, Nick Goeden, Ph.D., Nicholas Flytzanis in 2019.
Who are Capsida's investors?
Capsida's investors include Westlake Village BioPartners, Versant Ventures.